# The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study

> **NCT07078292** · — · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 400 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- Real World Study

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07078292
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07078292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07078292, "The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07078292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*